Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.

Christopher SongMario A CedilloKaren M LeeOctavia BaneStefanie HectorsWeiping MaPei WangDaniel StockerDarrell V MorrisDavid PinatoMax SungThomas MarronMyron SchwartzBachir Taouli

Published in: Abdominal radiology (New York) (2021)

Our results show ORR of 21%, equivalent for mRECIST, iRECIST, and RECIST1.1 in patients with advanced HCC clinically treated with nivolumab.

Keyphrases

immune response
locally advanced
combination therapy
open label
dendritic cells
liver metastases
toll like receptor
randomized controlled trial
squamous cell carcinoma
clinical trial
double blind